Less than five months after the FDA handed XenoPort Inc. and partner GlaxoSmithKline plc an unexpected complete response letter for gabapentin enacarbil in restless legs syndrome (RLS), the drug failed a Phase IIb trial in migraine prevention. (BioWorld Today) Read More
